Lapatinib is an oral small molecule dual targeted therapy that binds intracellularly to the ATP binding site of the EGFR and ErbB2 (HER2) receptors. In the EGF100151 trial, L+C improved time to progression (TTP) and progression free survival (PFS) vs C-only in women with ErbB2+ MBC who had received prior therapy including TZ. Following achievement of the primary endpoint, enrollment was halted, preventing demonstration of a significant difference in OS. METHODS: To inform ongoing analyses of the cost-effectiveness of L+C vs. C-only, Weibull survival functions for PFS and OS were fitted to observed failure time data from EGF100151 using Accelerated Failure Time (AFT) regression. Survival function parameters were estimated using a single regression equation for each outcome with treatment groups entered as an independent variable. Hazard Ratios (HRs) for progression and death with L+C were assumed to be proportionate to HRs for C-only. Expected PFS, OS, and post-progression survival (PPS) were calculated for each group. The validity of the Weibull model and PH assumption were assessed using graphical and analytical methods. RESULTS: Expected PFS, PPS and OS for L+C were 36.89, 43.78, and 80.67 weeks, respectively. Corresponding values for C-only were 22.49, 45.03, 67.47 weeks, respectively. Graphical tests of transformed survival functions supported use of Weibull distribution. Correlation tests between the ranked failure times and Schoenfeld residuals, supremum test for proportional hazards assumption, and comparisons of HRs for L+C vs. C-only by quarter postrandomization, provided no strong evidence of nonproportionality. CONCLUSION: Proportional hazards Weibull survival models are valid for modeling survival time data in patients with trastuzumab-refractory ErbB2-overexpressing MBC receiving L+C versus C-only, and suggest that lapatinib provides substantial benefit in terms of PFS and OS in patients with ErbB2+ MBC.
PCN10 CANCER RISK BETWEEN ATORVASTATIN AND SIMVASTATIN IN THE LOUISIANA MEDICAID PATIENTS
The University of Louisiana at Monroe, Monroe, LA, USA, 2 LSU Health Sciences Center, Shreveport, LA, USA OBJECTIVE: To compare the risk of cancer between Atorvastatin and Simvastatin users. METHODS: Retrospective cohort study was conducted in Louisiana Medicaid program from January 1, 1998 through June 30, 2005. Inclusion criteria were recipients continuously eligible with no more than two months gap, a paid claim for statin, and at least 40 years of age. Patients with diagnosis or drug claim for cancer in the washout period were excluded. Washout period was defined as a period between index date minus 12 months and index date plus 18 months. Statin (Atorvastatin or Simvastatin) users were patients with 300 or more days of supply of statin within 18 month period from the index date. Patients were then followed for at least six months or until end of study period. A propensity score-based matching method was used to match both the groups (1:1 match). Users of Atorvastatin were compared with the users of Simvastatin as to their risk of cancer. RESULTS: Each group had 1050 recipients after matching for comparison. Compared with Atorvastatin users, Simvastatin users experienced similar cancer risk (OR 1.20, 95% C.I. = 0.78-1.82). CONCLUSION: The data from present study provides evidence that there is no significant difference in risk of cancer between Atorvastatin and Simvastatin users. To evaluate the budget impact to a health plan after introducing Ixabepilone as a treatment option for metastatic breast cancer patients who have previously failed Anthracycline and Taxane based regimens. METHODS: The analysis was conducted from a U.S. payer's perspective over a three-year time horizon. The model specifically considered 2 segments of MBC patients for which Ixabepilone is indicated: 1) patients pretreated with Anthracycline and Taxane (AT_p); and 2) patients pretreated with Anthracycline, Taxane, and Capecitabine (ATC_p). After combining epidemiological data (SEERs, NCI), market uptake assumptions from market research forecasting, and current drug treatment costs (based on WAC price and average number of treatment cycles a patient received), the model estimated the incremental budget impact after adopting Ixabepilone as a treatment option. The model assumed that during the first year, 9.41% of AT_p patients receive Ixabepilone and Capecitabine combination therapy; and 62.7% of ATC_p patients are treated with Ixabepilone monotherapy. A plausible range of parameter values were considered in the sensitivity analysis. RESULTS: In a hypothetical health plan with approximately 0.06% of members estimated to be diagnosed with MBC, it was assumed that 37% were AT_p and 5% were ATC_p patients. In the year after introduction of Ixabepilone, the overall incremental cost per member per month (PMPM) was estimated to be approximately $0.03. For the AT_p patient segment, the incremental PMPM cost was estimated to be $0.03. However, for the ATC_p population, the model estimated a savings of $0.002 in PMPM. The incremental cost per treated MBC member per year is estimated at $545.29 for Year 1, and $640.76 and $668.01 for Years 2 and 3, respectively. CONCLUSION: In patients with MBC who have few viable treatment options after failing AT or ATC treatments, the budgetary impact of adding Ixabepilone to a health plan was estimated to be minimal. 2 . The costs of neutropenia and febrile neutropenia episodes were respectively US$1310.00 and US$6000.00. CONCLUSION: Besides the cost of the drug is a mean point in health resources utilization we have to consider other variables to have a clear picture of each chemotherapy scheme costs and were the resources have been used. Since the chance of toxicity is different for every kind of treatment, all the inputs to reach the total cost of treatment are necessary. 
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PCN12 USE OF HEALTH RESOURCES IN LUNG CANCER PATIENTS: A BRAZILIAN ANALYSIS IN THE PRIVATE PAYER PERSPECTIVE
CONCLUSION:
The financial impact of sorafenib to the provincial drug plans will range from $3.7 million to $9.7 million from 2008-2010. 
